According to China National Intellectual Property Administration News, the COVID-19 vaccine patent application jointly filed by Academician Chen Wei of the Academy of Military Medical Sciences and Kangxinuo Bio has been granted the patent right, which is the first COVID-19 vaccine patent in China.
The application name of this vaccine is "Recombinant novel coronavirus Vaccine with Human Replication Defective Adenovirus as Vector", which is an adenovirus vector vaccine (Ad5-nCoV vaccine) developed by Academician Chen Wei. According to the patent abstract, the invention provides a novel coronavirus vaccine with human replication-deficient adenovirus type 5 as the carrier.
The vaccine has good immunogenicity in mouse and guinea pig models and can induce strong cellular and humoral immune responses in a short time. In addition, the vaccine is fast and simple to prepare, and can be mass-produced in a short time to cope with the sudden epidemic. By the end of 2020, it is estimated that 300 million vaccines can be produced.
However, it is worth noting that beginning of autumn has passed. Once influenza merges in autumn, winter and spring in COVID-19, it will increase the difficulty of differential diagnosis, the social load of isolated people will increase obviously, the consumption of social resources will increase obviously, and the mortality rate will rise. So the most effective preventive measure at this time is to get the flu vaccine in time. Academician Wang Chen said, "Generally, influenza vaccine should be inoculated before the end of September, and no later than 10. It is a very important professional suggestion for us to comprehensively expand the vaccination population this year. "
In this battle, mankind will surely win!